OPIANT PHARMACEUTICALS, INC. | Business Contracts

Capacity Investment Agreement between Aptar Group Inc. and Opiant Pharmaceuticals, Inc. dated June 8, 2022 (Filed With SEC on August 11, 2022)

Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 15, 2022)

2021 Inducement Equity Incentive Plan, as amended on December 9, 2021 (Filed With SEC on December 13, 2021)

2021 Inducement Equity Incentive Plan and Form of Option Agreement (Filed With SEC on July 12, 2021)

Director Agreement, effective March 18, 2021, by and between Opiant Pharmaceuticals, Inc. and Dr. Lorianne Masuoka (Filed With SEC on March 22, 2021)

Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 4, 2021)

Amendment of Solicitation/Modification of Contract (Filed With SEC on December 14, 2020)

Note Purchase and Security Agreement, dated December 10, 2020, by and among Opiant Pharmaceuticals, Inc. and the parties named therein (Filed With SEC on December 10, 2020)

Registration Rights Agreement, dated December 10, 2020, by and among Opiant Pharmaceuticals, Inc. and the parties named therein (Filed With SEC on December 10, 2020)

Press Release of Opiant Press Release of Opiant Pharmaceuticals, Inc., dated November 12, 2020, Inc., dated November 12, 2020 (Filed With SEC on November 12, 2020)

Master Services Agreement dated October 26, 2020 between the Company and AptarGroup, Inc (Filed With SEC on October 29, 2020)

Master Services Agreement dated July 1, 2020 and Project Scope Agreement dated July 22, 2020 between the Company and Summit Biosciences, Inc (Filed With SEC on July 28, 2020)

Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 4, 2020)

Open Market Sale AgreementSM, dated November 14, 2019, by and between Opiant Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on November 14, 2019)

Amendment No. 2 to License Agreement, dated March 18, 2019, by and between Registrant and Adapt Pharma Operations Limited (Filed With SEC on March 21, 2019)

License Agreement between the Company and Sanofi dated December 21, 2018 (Filed With SEC on December 28, 2018)

Contract between the Company and Biomedical Advanced Research and Development Authority dated September 19, 2018 (Filed With SEC on December 4, 2018)

Director Agreement, effective October 29, 2018, by and between Opiant Pharmaceuticals, Inc. and Craig A. Collard (Filed With SEC on October 30, 2018)

Underwriting Agreement, dated as of September 25, 2018, by and between Opiant Pharmaceuticals, Inc. and Cantor Fitzgerald & Co (Filed With SEC on September 27, 2018)

Contract between the Company and Biomedical Advanced Research and Development Authority dated September 19, 2018 (Filed With SEC on September 20, 2018)

Development and Manufacturing Agreement between the Company and Aesica Queensborough Limited dated September 7, 2018 (Filed With SEC on September 10, 2018)

Agreement for Reimbursement of Capital Expenditures and Service Fees between the Company and Aesica Queensborough Limited dated September 7, 2018 (Filed With SEC on September 10, 2018)

Director Agreement, effective June 12, 2018, by and between Opiant Pharmaceuticals, Inc. and Richard Daly (Filed With SEC on June 12, 2018)

License Agreement between the Company and Adapt Pharma Operations Limited, dated as of December 15, 2014 (Filed With SEC on March 5, 2018)

Executive Employment Agreement, dated January 11, 2018, by and between Dr. Roger Crystal and Opiant Pharmaceuticals, Inc (Filed With SEC on January 16, 2018)

Executive Employment Agreement, dated January 11, 2018, by and between Mr. David OToole and Opiant Pharmaceuticals, Inc (Filed With SEC on January 16, 2018)

Executive Employment Agreement, dated January 11, 2018, by and between Dr. Phil Skolnick and Opiant Pharmaceuticals, Inc (Filed With SEC on January 16, 2018)

Forms of Incentive Stock Option Notice and Incentive Stock Option Agreement under the Opiant Pharmaceuticals, Inc. 2017 Long-Term Incentive Plan (Filed With SEC on December 4, 2017)

Forms of Nonstatutory Stock Option Notice and Nonstatutory Stock Option Agreement under the Opiant Pharmaceuticals, Inc. 2017 Long-Term Incentive Plan (Filed With SEC on December 4, 2017)

Form of Restricted Stock Agreement under the Opiant Pharmaceuticals, Inc. 2017 Long-Term Incentive Plan (Filed With SEC on December 4, 2017)

License Agreement, dated as of June 22, 2017, by and between the Company and Aegis Therapeutics, LLC (Filed With SEC on October 13, 2017)

Supply Agreement, dated as of June 22, 2017, by and between the Company and Aegis Therapeutics, LLC (Filed With SEC on October 13, 2017)

Research and Development Agreement, dated as of July 14, 2017, by and between the Company and Renaissance Lakewood, LLC (Filed With SEC on October 13, 2017)

Separation Agreement and General Release, dated as of September 5, 2017, by and between the Company and Kevin Pollack (Filed With SEC on October 13, 2017)

Opiant Pharmaceuticals, Inc. 2017 Long-Term Incentive Plan (Filed With SEC on October 13, 2017)

Agreement and Plan of Merger, dated October 2, 2017, by and between Opiant Pharmaceuticals, Inc., a Nevada corporation, and Opiant Pharmaceuticals, Inc., a Delaware corporation (Filed With SEC on October 6, 2017)

Supplemental Engagement Letter, dated September 8, 2017, by and between the Company and Torreya Partners (Europe) LLP (Filed With SEC on September 14, 2017)

Sublease, effective as of August 1, 2017, by and between Opiant Pharmaceuticals, Inc. and Standish Management, LLC, as amended by that certain letter agreement, dated as of August... (Filed With SEC on September 5, 2017)

Offer Letter, dated August 29, 2017, by and between the Company and David OToole (Filed With SEC on September 5, 2017)

THIRD AMENDMENT TO SENIOR ADVISOR AGREEMENT (Filed With SEC on June 14, 2017)

AMENDMENT TO INVESTMENT AGREEMENT (Filed With SEC on June 2, 2017)

AMENDMENT TO AMENDED AND RESTATED CONSULTINGAGREEMENT (Filed With SEC on June 2, 2017)

LICENSE AGREEMENT between LIGHTLAKETHERAPEUTICS INC. and ADAPT PHARMA OPERATIONS LIMITED Dated as of December 15, 2014 (Filed With SEC on April 19, 2017)

AMENDMENT NO. 1 TO LICENSE AGREEMENT (Filed With SEC on April 19, 2017)

AMENDMENT TO INVESTMENT AGREEMENT (Filed With SEC on April 18, 2017)

Employment Agreement Acknowledgement (Filed With SEC on April 6, 2017)

PURCHASE AND SALE AGREEMENT dated as of December 13, 2016 between OPIANT PHARMACEUTICALS, INC. and SWKFunding LLC (Filed With SEC on March 15, 2017)

AMENDMENT NO. 1 TO LICENSE AGREEMENT (Filed With SEC on March 15, 2017)

THIRD AMENDMENT TO SENIOR ADVISOR AGREEMENT (Filed With SEC on March 15, 2017)

Senior Advisor Agreement (Filed With SEC on March 15, 2017)

First Amendment toSenior Advisor Agreement (Filed With SEC on March 15, 2017)

SecondAmendment to Senior Advisor Agreement (Filed With SEC on March 15, 2017)

Employment Agreement (Filed With SEC on February 6, 2017)

OPIANT PHARMACEUTICALS, INC. DIRECTOR AGREEMENT (Filed With SEC on November 10, 2016)